Shots:

• The P-IIa EPICCURE trial evaluates safety, tolerability & exploratory efficacy of epicardial inj. of AZD8601 vs PBO in 11 patients (7 were treated with AZD8601 & 4 received PBO inj.) with stable CAD & decreased LVEF who undergoes CABG surgery. The therapy is being co-developed with Moderna
• The study met its 1EPs i.e., numerical trends were identified in 3 exploratory efficacy EPs over PBO, including an increase in LVEF & functional PROs, 7 patients treated with AZD8601 had NT-proBNP
• AZD8601 is a novel mRNA-based therapy that encodes for VEGF-A. AstraZeneca has signed an exclusive agreement with Moderna to discover & commercialize mRNA therapeutics for multiple diseases

  Ref: AstraZeneca | Image: Mint